NASDAQ OMX

Merus Announces Final Ruling in Inequitable Conduct Case Against Regeneron

4.11.2015 01:01 | NASDAQ OMX

Del

UTRECHT, The Netherlands, 2015-11-04 01:01 CET (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the U.S. District Court for the Southern District of New York has issued its full written opinion in the Company's inequitable conduct case against Regeneron Pharmaceuticals, Inc. On August 6, 2015, Judge Katherine B. Forrest ruled that Regeneron engaged in inequitable conduct in connection with obtaining U.S. Patent No. 8,502,018 (the '018 patent), entitled "Methods of Modifying Eukaryotic Cells." In the full written opinion, issued yesterday, Judge Forrest has concluded that Regeneron engaged in inequitable conduct by withholding material information with an intent to deceive the United States Patent and Trademark Office while prosecuting the '018 patent, stating that "[b]ased upon the Court's assessment of the evidence, it appears that the very birth of this patent was beset by misconduct as well. And so it has come full circle. That which was obtained by misconduct ends as a result of misconduct." Judge Forrest further stated that "the disclosures in the specifications of the '018 [p]atent were… insufficient to practice the invention," and based on certain evidence, concluded that Regeneron made false and misleading statements, which constituted egregious affirmative misconduct.

On March 11, 2014, Regeneron filed a complaint against Merus alleging that it infringed one or more claims in the '018 patent. On July 3, 2014, Merus filed a response to Regeneron's complaint, denying Regeneron's allegations of infringement and raising affirmative defenses. Merus also filed counterclaims seeking, among other things, a declaratory judgement that Merus did not infringe the '018 patent and that the '018 patent was invalid. Merus subsequently filed amended counterclaims seeking a declaratory judgement of unenforceability of the '018 patent due to Regeneron's commission of inequitable conduct. Regeneron's '018 patent had previously been adjudged to be not infringed and that it was invalid. Yesterday's final ruling in Merus' favor renders the '018 patent unenforceable for being procured by inequitable conduct.

About Merus B.V.

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. Biclonics are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional IgG-based antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128 is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia, and Merus expects to initiate clinical trials of this candidate in the first quarter of 2016. The company also has a robust pipeline of proprietary bispecific antibody candidates in pre-clinical development, including Biclonics designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.

CONTACT: Investors:
         Merus B.V.
         Shelley Margetson - s.margetson@merus.nl
         +31 (0)30 253 8800
         
         Media:
         Argot Partners
         Eliza Schleifstein - eliza@argotpartners.com
         1-917-763-8106

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00Pressemelding

CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go

Ascom Myco and Koutio Médipôle optimize care communications and responsiveness16.8.2017 08:00Pressemelding

Ascom Holding AG / Ascom Myco and Koutio Médipôle optimize care communications and responsiveness . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Enabled by the Ascom Myco smart device, the new Koutio Médipôle is realizing improved care delivery through seamless information flow from the point of care to anywhere. BAAR, Switzerland, Aug. 16, 2017 (GLOBE NEWSWIRE) -- The new Koutio Médipôle hospital in the New Caledonian capital Nouméa, located in the southwest Pacific Ocean, has optimized patient care communications and responsiveness for the new 645-bed facility by deploying Ascom Myco Wi-Fi devices to support clinician teams and Ascom Myco Wi-Fi/GSM handsets, used across paramedic teams. The Ascom solution is seamlessly aligned with clinical workflow and applications (nurs

VistaJet Harnesses the Power of the American Eclipse to Offer Customers a Rare Viewing Opportunity15.8.2017 18:40Pressemelding

VistaJet invites customers to fly in parallel with an astronomical anomaly NEW YORK, Aug. 15, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, will be offering customers the opportunity to experience and chase the American Solar Eclipse, appearing for the first time in 99 years on August 21, 2017. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c0c41d7d-7ad9-4a46-9d2d-dcc1148b4772 The coast-to-coast National Eclipse and astronomical phenomenon will be visible in the United States from approximately 10:15AM PST, with the sun disappearing behind the moon from the Oregon coast, passing through 14 states to South Carolina.  Without being in this 70-mile strip, Americans will not be able to see the sun eclipsed in totality. With unparalleled experience flying into and out of the hardest to reach destinations, VistaJet is offer

NGX Bio Raises $3 Million to Fund Growth of Its DNA Sequencing Marketplace15.8.2017 17:00Pressemelding

SAN FRANCISCO, Aug. 15, 2017 (GLOBE NEWSWIRE) -- NGX Bio, Inc., (www.NGXbio.com) the premier marketplace for online DNA sequencing services, announced it has closed a $3 million funding round.  The round was led by 180 Degree Capital Corp. (NASDAQ:TURN) and included Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, as well as other investors. NGX Bio was founded in 2014 to provide streamlined, on-line access to next-generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing of both human and non-human samples globally.  Demand for sequencing services is growing exponentially.  NGX Bio's platform matches the sequencing needs of customers with providers who have available sequencing capacity.  Customers are able to purchase a wide range of sequencing services for their samples using NGX Bio's online ordering tools.  NGX Bio offers these services through numerous and deep relationships with its

Hminers Launch the Most Powerful Cryptocurrency Mining Rigs with Unique Features15.8.2017 15:57Pressemelding

Hminers has just introduced three new mining rigs with extraordinary features. The company already has the unique distinction of delivering the first ever 10nm ASIC mining rig in the cryptocurrency market. MIAMI, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Hminers is delighted to announce the mega launch of three new products that will make cryptocurrency mining easy and efficient like never before. This Miami-based organization is one of the most trusted names in the cryptocurrency market with the distinction of creating the world's first 10 nm ASIC Chip. The company's three new products H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U are now up for sale at www.Hminers.com. As the difficulties in bitcoin mining have kept on increasing over the last few years, Hminers has embraced new principles to create multi algorithm based miners. Each of the three new products from the company is built and designed to operate under multiple algorithms and provide custome

Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares15.8.2017 15:02Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the pricing of its previously announced underwritten public offering of 2,500,000 ordinary shares pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The aggregate gross proceeds to Oxford Immunotec, before deducting the underwriting discounts and commissions and offering expenses, will be $40.125 million. The offering is expected to close on or about August 18, 2017, subject to customary closing conditions. In addition, Oxford Immunotec has granted BTIG, LLC, the sole underwriter of the offering, an option to purchase up to 375,000 additional ordinary shares. Oxford Immunotec intends to use th

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom